الفهرس 
AbstractOnly 14 pages are availabe for public view
 |  | from | 120 |  |  |
| | | from | 120 | | |
Abstract
SUMMARY
The coronavirus 2019 disease (COVID-19) represents a serious public health issue worldwide. As well known, diabetic patients are at higher risk of infection especially during period of poor glycaemic controls. Recent investigations have reported that in COVID-19 infection, diabetes mellitus (DM) is one of the most common comorbidities.
This study was conducted at Beni-Suef University hospital on 40 patients with confirmed COVID 19 to assess the impact of diabetes on course of COVID-19 disease in critically ill patients by measuring of HbA1c in first 48 hours of admission and follow up severity of the disease. The mean age of the studied patients was 60.2±14.5 years, 52.5 % of the participants were males.
The study showed that uncontrolled DM indicated by high levels of HbA1C were associated with the severity of the disease and high mortality rate. The mean level of HbA1C for diabetic patients was 9.5±1.2. There was a significant association between the higher HbA1c level (>8.7) and need to mechanical ventilation, higher length of stay in ICU and the mortality in diabetic patients.
There was a statistically significant difference between both groups as regards the APACHII score. The score was higher for diabetic patients and reached an average of 20.6±6.3 unlike the non-diabetic patients who had an average of 13.2±4.5.
The progress of the condition and need to mechanical ventilation was observed in 35% of the studied patients. The mean length of stay was 19.4±12.5days and the mortality was 32.5% among the studied patients.
The values of IL-6, LDH, CRP and D-dimer were elevated in both groups with no statistically significant differences. There were statistically significant differences between both groups regarding the ferretin and pro-calcitonin. TLC for diabetic patients was 8.2±4.4, CRP 104.6±102.8, D-dimer 1.7±1.2, Ferretin 953.3±169.4, LDH 601.3±265.8, pro-calcitonin 0.6±0.3 and IL-6 101.4±97.6.
The CORADs score was 4.5±0.7. All patients were positive PCR. 62.5% of patients were COARDs V and 32.5% were COARDs IV. 2.5% of patients were COARDs III and the same percent for COARDs II. There was no significant increase in CORADs score from the first to the second assessment in non-diabetic patients but in diabetic group, there was a significant increase of CORADs score.